Vectans Pharma is proud to announce that Fimea (Finnish Medicines Agency) has granted OTC status to its Lauriad^® aciclovir treatment tablet for herpes labialis, Sitavig^® 50mg, as a one-per-episode treatment.

"I am pleased to share the news of Sitavig^® receiving OTC status in Finland with our partner, Navamedic ASA . This achievement reflects our collective effort and provides a unique opportunity to offer patients access to an innovative treatment," states Vectans Pharma's Director of Regulatory and Industrial Affairs, Jonathan Cohen.

Following Italy and France, Finland is now the third country to grant OTC status upon Lauriad^® Aciclovir, while we await further agreements in our global switch projects.

Vectans Pharma is delighted to collaborate with the Menarini group and Berlin Chemie for the commercialization of Sitavig^® in Italy and Austria.

Vectans Pharma wishes you a happy and healthy New Year!

Vectans Pharma will be present at the CPhI worldwide in Frankfurt from November 01 to 03, 2022.

Vectans Pharma is delighted to collaborate withBerlin Chemie expanding the international scope of Sitavig® to 30 additional countries.

Read the press release

We are thrilled to welcome Medine Kockan as our new intern in Marketing and Strategic Innovation!

She will contribute to the many projects of our team. We are excited for her to participate in our continued growth!

Vectans pharma is proud to announce that its one-per-episode Lauriad^® aciclovir treatment tablet for herpes labialis, Sitavig^® 50mg, has received the approbation of the ANSM for OTC commercialization in France. Issued from Lauriad technology, SITAVIG ensures an optimum and efficient localized concentration of acyclovir directly at the disease site.
A big step for Vectans , but also for the many patients in France prone to recurrent

Because changing the way medicines are delivered can improve patient’s life drastically. With Lauriad^® we are committed to optimizing the existing therapeutic offer, bringing out new « best-in-disease » drugs.